🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Acute Lymphoblastic Leukemia, in Relapse

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406Phase 21 site📍 Beijing Hebei Senlang Biotechnology Inc., Ltd. · Tests: S1904 CD19 CAR-T CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites📍 Beijing📍 Beijing📍 Chongqing Chongqing Precision Biotech Co., Ltd · Tests: pCAR-19B cells CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site📍 Riyadh King Faisal Specialist Hospital & Research Center · Tests: CAR T cells chimeric antigen receptor cells A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 328 sites📍 Toronto📍 Copenhagen📍 Aarhus Nord Merck Sharp & Dohme LLC · Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) NCT06561074Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Venetoclax, Calaspargase pegol-mknl SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: supCD7 CART cells A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites📍 Hefei📍 Chongqing📍 Guangzhou Juventas Cell Therapy Ltd. · Tests: single dose of CNCT19 Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites📍 Tübingen📍 Tübingen University Hospital Tuebingen · Tests: CAR-T cells targeting CD19 and CD22 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biospecimen Collection, Pomalidomide Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: CAR-T cell Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD5/CD7 CAR-T Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885Phase 1, Phase 22 sites📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: CAR19TIF cells, Fludarabine, Cyclophosphamide A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy NCT04227015EARLY Phase 11 site📍 Hangzhou He Huang · Tests: CTA101 Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284n/a3 sites📍 London📍 London📍 Manchester University College, London Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL NCT06880913Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Nanobody-Based CD19/CD22 Tandem Dual CAR-T First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. NCT07586618Phase 17 sites📍 Aurora📍 Indianapolis📍 New York Allterum Therapeutics, Inc · Tests: 4A10 Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT06934382Phase 11 site📍 Philadelphia Stephan Grupp MD PhD · Tests: Allogeneic anti-CD7 CAR-T cells (BEAM-201) UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site📍 Aurora University of Colorado, Denver · Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites📍 Beijing📍 Shanghai📍 Shanghai Beijing GoBroad Hospital · Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474Phase 11 site📍 Wuhan Chongqing Precision Biotech Co., Ltd · Tests: Anti-CD5 CAR NK cells Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia NCT06816134Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: TmBU conditioning Regimen, mBUCY conditioning regimen Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735Phase 1, Phase 26 sites📍 Beijing📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia NCT05512169n/a2 sites📍 New Delhi📍 Puducherry University of Geneva, Switzerland HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites📍 Vienna📍 Ghent📍 Copenhagen Princess Maxima Center for Pediatric Oncology · Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy